Key Takeaways
- • Reed Jobs, 34, operates Yosemite, a $1 billion+ oncology-focused venture capital fund, and is actively pursuing investment opportunities in UK cancer care and life sciences research.
- • Yosemite has already deployed capital into approximately 20 healthcare startups across gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence, with confirmed US investments in Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care, plus undisclosed UK portfolio companies.
- • The fund receives institutional backing from LifeArc, a UK-based not-for-profit focused on rare diseases, and maintains philanthropic partnerships with Oxford and Cambridge universities, positioning it as a bridge between US venture capital and UK academic research infrastructure.
- • Reed Jobs' investment thesis is motivated by personal experience—his father Steve Jobs died of pancreatic cancer in 2011 at age 56—reflecting a mission to transform cancer from a terminal to a manageable, treatable disease.
- • Yosemite operates a dual-structure model: a for-profit venture capital arm investing in healthcare companies and a donor-advised fund awarding grants to early-stage cancer researchers, enabling both commercial returns and philanthropic impact.
Summary
Reed Jobs, son of late Apple co-founder Steve Jobs, is directing his $1 billion+ oncology-focused venture capital fund, Yosemite, toward expanded investment in UK cancer care and life sciences research. The 34-year-old founded the San Francisco-based firm with a mission rooted in personal tragedy: witnessing his father's death from pancreatic cancer in 2011 at age 56. This formative experience has shaped Jobs' strategic focus on transforming cancer outcomes through venture-backed innovation.
Yosemite has already accumulated a portfolio of approximately 20 healthcare startups, spanning multiple oncology-adjacent disciplines including gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence applications. Confirmed US investments include Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care; the fund has also made undisclosed investments in UK-based companies. The fund's international deployment strategy reflects Jobs' belief that innovation in cancer treatment transcends geographic boundaries and that UK-based research represents a significant opportunity.
The fund's UK expansion is facilitated by institutional relationships with LifeArc, a not-for-profit organization historically focused on rare disease research and established through the UK's Medical Research Council in 2000. Yosemite receives investment capital from LifeArc and maintains philanthropic partnerships with Oxford and Cambridge universities, through which it has awarded grants to early-stage researchers. Jobs' public endorsement of UK research infrastructure—"Research here is world class"—underscores the strategic importance of these partnerships in accessing pipeline opportunities and academic talent.
Yosemite operates a hybrid investment structure combining a for-profit venture capital vehicle with a donor-advised fund that deploys philanthropic capital toward early-stage cancer research. This dual model enables the firm to access both commercial investment returns and tax-advantaged philanthropic capital, creating capital efficiency while supporting fundamental research that may lack immediate commercial viability. Jobs' presence at LifeArc's London-based life sciences conference signals active deal sourcing and relationship building aimed at identifying UK-based oncology companies meeting Yosemite's investment criteria.
Yosemite has already accumulated a portfolio of approximately 20 healthcare startups, spanning multiple oncology-adjacent disciplines including gene therapy, cancer vaccines, radiopharmaceuticals, and artificial intelligence applications. Confirmed US investments include Tune Therapeutics, Azalea Therapeutics, Chai Discovery, and Sage Care; the fund has also made undisclosed investments in UK-based companies. The fund's international deployment strategy reflects Jobs' belief that innovation in cancer treatment transcends geographic boundaries and that UK-based research represents a significant opportunity.
The fund's UK expansion is facilitated by institutional relationships with LifeArc, a not-for-profit organization historically focused on rare disease research and established through the UK's Medical Research Council in 2000. Yosemite receives investment capital from LifeArc and maintains philanthropic partnerships with Oxford and Cambridge universities, through which it has awarded grants to early-stage researchers. Jobs' public endorsement of UK research infrastructure—"Research here is world class"—underscores the strategic importance of these partnerships in accessing pipeline opportunities and academic talent.
Yosemite operates a hybrid investment structure combining a for-profit venture capital vehicle with a donor-advised fund that deploys philanthropic capital toward early-stage cancer research. This dual model enables the firm to access both commercial investment returns and tax-advantaged philanthropic capital, creating capital efficiency while supporting fundamental research that may lack immediate commercial viability. Jobs' presence at LifeArc's London-based life sciences conference signals active deal sourcing and relationship building aimed at identifying UK-based oncology companies meeting Yosemite's investment criteria.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.